Cabo Verde
Tuberculosis profile
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.11 (0.047–0.21) 23 (9.5–42)
Mortality (HIV+TB only) 0.024 (0.02–0.031) 4.8 (4.1–6.2)
Prevalence  (includes HIV+TB) 1.2 (0.59–2) 237 (119–395)
Incidence  (includes HIV+TB) 0.71 (0.59–0.85) 144 (119–172)
Incidence (HIV+TB only) 0.071 (0.058–0.086) 14 (12–17)
Case detection, all forms (%) 59 (49–72)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 189 (47) Relapse 14 (74)
Smear-negative 130 (32) Treatment after failure 5 (26)
Smear-unknown / not done 21 (5) Treatment after default 0 (0)
Extrapulmonary 66 (16) Other 0 (0)
Other 0 (0)      
Total new 406   Total retreatment 19  
           
Other (history unknown) 0        
Total new and relapse 420   Total cases notified 425  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.4 2.4 1.8
Age < 15 0 21 11
Laboratories 2012
Smear (per 100 000 population) 3.2
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 77   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 51  
Retreatment 37  
TB/HIV 2012 Number (%)
TB patients with known HIV status 378 (89)
HIV-positive TB patients 45 (12)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 20 (44)
HIV-positive TB patients on antiretroviral therapy (ART) 44 (98)
HIV-positive people screened for TB 44  
HIV-positive people provided with IPT 123  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
6 (0–12) 4 (1–6)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 81%
% Funded internationally 19%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data